drugset / Trial / NCT02267902
Microtracer Study to Establish Absolute Bioavailability and the Absorption, Metabolism, Excretion of DA-1229
Non-randomizedParallel-groupOpen-labelScreening
Summary
The objectives of this study are to evaluate the absolute bioavailability, and absorption and excretion of DA-1229, an IMP in clinical assessment for the treatment of T2DM. The oral and IV PK of DA-1229 will also be evaluated. The metabolism of DA-1229 may also be evaluated.
Timeline
- Start
- 2014-09
- Primary completion
- 2015-01
- Completion
- 2015-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Evogliptin | Small molecule | 20 ug | Oral |
| Subject | Evogliptin | Small molecule | 5 mg | Oral |
Indications
No indication recorded.